TNG:EPA
Transgene SA
0,68 €
arrow_downward
−0,73%(−0,0050) 1 D
19. okt., 17:35:04 GMT+2 · EUR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for TNG …
Åpne
0,69 €
Høy
0,70 €
Lav
0,68 €
Markedsverdi
191,94 mill.
Snittvolum
111,65k
Volum
53,57k
52 u høy
1,50 €
52 u lav
0,68 €
EPS
−0,17 €
Utestående aksjer
278,56 mill.
Antall ansatte
152
Åpne
0,69 €
Høy
0,70 €
Lav
0,68 €
Markedsverdi
191,94 mill.
Snittvolum
111,65k
Volum
53,57k
52 u høy
1,50 €
52 u lav
0,68 €
EPS
−0,17 €
Utestående aksjer
278,56 mill.
Antall ansatte
152
Nyhetssaker
Fra nettkilder og nyhetspartnere
CNBC
·
for 1 time siden
CNBC Daily Open: Tech investors buy the dip — but debt remains a concern
Simply Wall Street
·
for 6 minutter siden
Strive (ASST) Stock Could Look Pricey Following Its SATS Stock Offering
bloomingbit
·
for 1 time siden
Dunamu Sets Up US Investment Unit, Distances Move From Nasdaq Listing Speculation
Bloomberg.com
·
for 4 timer siden
US Stock Futures Edge Higher After Chipmaker Rally: Markets Wrap
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Om Transgene SA